{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:23:44Z","timestamp":1788715424285,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0373"],"award-info":[{"award-number":["2021YFS0373"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to review the treatment plan of patients with multidrug-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (MDR-AB) pneumonia and analyze the factors associated with patient deaths and the medication regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected 1,823 qualified respiratory specimens that were culture-positive for MDR-AB. 166 patients confirmed to have hospital-acquired MDR-AB pneumonia were selected as the research subjects. The differing clinical characteristics and treatment interventions between the surviving group and death group within 28 days were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mortality rate was high for those aged\u2009&gt;\u200975 years (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Patients who underwent invasive catheter placement (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and mechanical ventilation (<jats:italic>p<\/jats:italic>\u2009=\u20090.046) had a higher mortality rate. Combination therapy with tigecycline can reduce the mortality rate (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) of MDR-AB pneumonia in patients with carbapenem-resistant AB(CRAB). Combination therapy with sulbactam was shown to reduce the mortality rate (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and high-dose sulbactam (&gt;\u20093\u00a0g\/day) might be better than low-dose sulbactam (\u2264\u20093\u00a0g\/day).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07778-5","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:04:05Z","timestamp":1666343045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanling","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"7778_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nrmicro1789","volume":"5","author":"L Dijkshoorn","year":"2007","unstructured":"Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939\u201351. doi:https:\/\/doi.org\/10.1038\/nrmicro1789.","journal-title":"Nat Rev Microbiol"},{"key":"7778_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9:119. doi:https:\/\/doi.org\/10.3390\/antibiotics9030119.","journal-title":"Antibiotics"},{"key":"7778_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/IDR.S166750","volume":"11","author":"M Asif","year":"2018","unstructured":"Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249\u201360. doi:https:\/\/doi.org\/10.2147\/IDR.S166750.","journal-title":"Infect Drug Resist"},{"key":"7778_CR4","first-page":"3","volume":"2","author":"B Chen","year":"2012","unstructured":"Chen B, He L, Hu B, Ni Y, Qiu H, Shi Y, et al. Expert consensus on diagnosis, treatment, prevention and control of Acinetobacter baumannii infection in China. China Med Pharm. 2012;2:3\u20138. (in Chinese).","journal-title":"China Med Pharm"},{"key":"7778_CR5","doi-asserted-by":"publisher","unstructured":"Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E. Multidrug resistant Acinetobacter baumannii: Resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21. doi:https:\/\/doi.org\/10.1007\/s11908-019-0706-5.","DOI":"10.1007\/s11908-019-0706-5"},{"key":"7778_CR6","unstructured":"Hu F, Guo Y, Wu S, Yang Y, Zheng Y, Yin D, et al. CHINET results of bacterial resistance surveillance in 2020 (full year), CHINET; 2020 (in Chinese). Available at: http:\/\/www.chinets.com\/Content\/File\/CHINET%202020%E5%B9%B4%E7%BB%86%E8%8F%8\u00a0C%E8%80%90%E8%8D%AF%E7%9B%91%E6%B5%8B%E7%BB%93%E6%9E%9\u00a0C%EF%BC%88%E5%85%A8%E5%B9%B4%EF%BC%89.ppt. Accessed August 17, 2021."},{"key":"7778_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect Dis. 2014;14:102. doi:https:\/\/doi.org\/10.1186\/1471-2334-14-102.","journal-title":"BMC Infect Dis"},{"key":"7778_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3760\/cma.j.issn.1001-0939.2018.04.006","volume":"41","author":"Infectology Group of Respiratory Diseases Branch of Chinese Medical Association (CMA)","year":"2018","unstructured":"Infectology Group of Respiratory Diseases Branch of Chinese Medical Association (CMA). Guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in Chinese adult hospitals (2018 edition). Chin J Tuberc Respir Dis. 2018;41:255\u201380. doi:https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2018.04.006. (in Chinese).","journal-title":"Chin J Tuberc Respir Dis"},{"key":"7778_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-017-2932-5","volume":"18","author":"H Huang","year":"2018","unstructured":"Huang H, Chen B, Liu G, Ran J, Lian X, Huang X, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infect Dis. 2018;18:11. doi:https:\/\/doi.org\/10.1186\/s12879-017-2932-5.","journal-title":"BMC Infect Dis"},{"key":"7778_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5414\/cp202557","volume":"55","author":"P Li","year":"2017","unstructured":"Li P, Wang X, Wang W, Zhao X. Comparison of the efficacies of three empirically-selected antibiotics for treating Acinetobacter baumannii pulmonary infection: Experience from a teaching hospital in China. Int J Clin Pharmacol Ther. 2017;55:588\u201393. doi:https:\/\/doi.org\/10.5414\/cp202557.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"7778_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","volume":"47","author":"W Ni","year":"2016","unstructured":"Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47:107\u201316. doi:https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.11.011.","journal-title":"Int J Antimicrob Agents"},{"key":"7778_CR12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/ccm.0000000000000933","volume":"43","author":"A Cheng","year":"2015","unstructured":"Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia. Crit Care Med. 2015;43:1194\u2013204. doi:https:\/\/doi.org\/10.1097\/ccm.0000000000000933.","journal-title":"Crit Care Med"},{"key":"7778_CR13","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/jam.15130","volume":"131","author":"M Nguyen","year":"2021","unstructured":"Nguyen M. S.G.Joshi. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131:2715\u201338.","journal-title":"J Appl Microbiol"},{"key":"7778_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jac\/dkh080","volume":"53","author":"WC Ko","year":"2004","unstructured":"Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53:393\u20135. doi:https:\/\/doi.org\/10.1093\/jac\/dkh080.","journal-title":"J Antimicrob Chemother"},{"key":"7778_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.13286\/j.cnki.chinhosppharmacyj.2019.07.05","volume":"39","author":"J Li","year":"2019","unstructured":"Li J, Situ B, Guo X, Zeng X, Tan X. In vitro activity of Sulbactam in combination with nine antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Chin J Hosp Pharm. 2019;39:676\u201381. doi:https:\/\/doi.org\/10.13286\/j.cnki.chinhosppharmacyj.2019.07.05. (in Chinese).","journal-title":"Chin J Hosp Pharm"},{"key":"7778_CR16","doi-asserted-by":"publisher","first-page":"104940","DOI":"10.1016\/j.ejps.2019.05.018","volume":"136","author":"S Jaruratanasirikul","year":"2019","unstructured":"Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii. Eur J Pharm Sci. 2019;136:104940. doi:https:\/\/doi.org\/10.1016\/j.ejps.2019.05.018.","journal-title":"Eur J Pharm Sci"},{"key":"7778_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/00365540600951184","volume":"39","author":"AP Betrosian","year":"2007","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis. 2007;39:38\u201343. doi:https:\/\/doi.org\/10.1080\/00365540600951184.","journal-title":"Scand J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07778-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07778-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07778-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:04:14Z","timestamp":1666343054000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07778-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7778"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07778-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"19 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective research was conducted in compliance with the Declaration of Helsinki and the Ethical Guidelines for Medical Research Involving Human Subjects. This research was approved by the ethics committee of Sichuan Provincial People\u2019s Hospital (which affiliated to the University of Electronic Science and Technology of China: Approval number 2019059B). We applied the opt-out approach to obtain consent from participants. The ethics committee of Sichuan Provincial People\u2019s Hospital waived the need for specific informed consent for this retrospective, non-invasive study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable since the manuscript does not include information or images that could lead to the identification of a study participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"795"}}